Cat. No. | Product name | CAS No. |
DC66817 |
Ebdarokimab
Featured
Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells. |
|
DC66818 |
Lebrikizumab
Featured
Lebrikizumab is an IgG4 humanized monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its function. Lebrikizumab can be used for the research of asthma. |
953400-68-5 |
DC66819 | IMA-026 Featured | |
DC66820 | GSK 679586 Featured | |
DC66821 |
Abrezekimab
Featured
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma. |
2043952-59-4 |
DC66822 |
Cendakimab
Featured
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). |
2151032-62-9 |
DC66823 |
Dectrekumab
Featured
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research. |
1528523-94-5 |
DC66824 | CNTO 6079(Anti-IL-13 Antibody) Featured | |
DC66826 |
Tralokinumab
Featured
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD). |
1044515-88-9 |
DC66827 | H2L6(Anti-IL-13 Antibody) Featured | |
DC66828 | M129(Anti-IL-13 Antibody) Featured | |
DC66829 | Eblasakimab (MK-6105) Featured | |
DC66830 | Wake Forest U. patent anti-IL-13RA2 Featured | |
DC66831 |
Ordesekimab
Featured
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD). |
879293-15-9 |
DC66832 | Anti-IL-15 Antibody (DISC0280) Featured | |
DC66833 |
Brodalumab
Featured
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis. |
1174395-19-7 |
DC66834 | GSK 1070806 Featured | |
DC66835 | ABT-325 Featured | |
DC66836 |
Gevokizumab
Featured
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). |
1129435-60-4 |
DC66837 | CDP484 Featured | |
DC66838 |
Canakinumab
Featured
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin. |
914613-48-2 |
DC66839 | AMG 108 Featured |